About this Book

The implication of tumour microenvironment (TME) on cancer progression and therapeutic response has profoundly shifted the paradigms of molecular cancer research and drug discovery. The intricate networks of immune-inflammatory cells and signalling, cancer-associated fibroblasts, endothelial cells and adipose cells are extensively researched for diagnostics, therapeutics and predictive values. This includes siRNA and miRNA nanotherapeutics targeting these molecular components, owing to their powerful gene-silencing properties. Despite the concerted effort in the development of drug targeting TME, such as BLZ945 (a colony-stimulating factor-1 receptor inhibitor), there is a void in clinically satisfactory drug to target this intricate factor, thus far.